Nottingham, United Kingdom

Roger Bernard Titman

This inventor holds 2 USPTO granted patents. Top assignees: Knoll Aktiengesellachaft, The Boots Company Plc. Active years: 1988-1998.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1988-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Roger Bernard Titman: Innovator in Pharmaceutical Chemistry

Introduction

Roger Bernard Titman is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 2 patents, Titman has focused on developing compounds with therapeutic applications.

Latest Patents

Titman's latest patents include "Azolyl-cyclic amine derivatives with immunomodulatory activity." This patent describes a compound with immunomodulatory activity, along with pharmaceutical compositions and processes for its use. Another significant patent is for "Antiulcer benzimidazole derivatives," which details compounds that serve as histamine H2-receptor antagonists, showcasing his expertise in creating effective pharmaceutical agents.

Career Highlights

Throughout his career, Titman has worked with prominent companies such as The Boots Company Plc and Knoll Aktiengesellschaft. His experience in these organizations has allowed him to refine his skills and contribute to the development of innovative pharmaceutical solutions.

Collaborations

Titman has collaborated with notable professionals in his field, including Michael Henry Hockley and Roy V Davies. These partnerships have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Roger Bernard Titman is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable patents and collaborations. His contributions continue to impact the field positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…